23andMe to receive up to $60M from pharma company Genentech to provide genetic data for Parkinson's research
Context & Ripple Effects
This Forbes report captures 23andMe at the moment its real business model crystallized: not selling kits, but selling access to its customer DNA database, with Genentech paying up to $60M for Parkinson's-relevant genetic data. It was the first proof that the asset was the cohort, not the consumer product.
That thesis ran the company's arc from there — through a $3.5B SPAC valuation in 2021, into Chapter 11, and finally to the database itself being auctioned, where Regeneron's $256M winning bankruptcy bid was topped when Wojcicki-backed TTAM Research Institute offered $305M. The Genentech deal is the origin point of the very asset whose ownership regulators and users fought over in the 2025 auction.
First-order effects
- Genentech gains direct access to 23andMe's Parkinson's patient genetic data for research, bypassing years of traditional patient recruitment.
- 23andMe converts its accumulated consumer dataset into a major pharma revenue contract, validating data licensing as its core business alongside kit sales.
Second-order effects
- Other pharmaceutical companies now have a template for buying genetic cohorts directly from consumer-genomics firms, pushing 23andMe toward more data-access deals as its primary growth line.
- The deal raises the market value of large consented genetic databases generally, which is precisely what later made the database the only asset worth bidding on once 23andMe entered bankruptcy.
Third-order effects
- If the pattern holds, consumer genetics companies end up functioning as data brokers whose ultimate value sits in the database — meaning control of user genetic data passes to whoever wins the next acquisition or auction, as the 2025 bidding war between Regeneron and TTAM demonstrated.
- Deals like this foreshadow the governance question that surfaced in the bankruptcy coverage: whether customers who consented to research with one company have effectively consented to their data being owned by its future buyers.
The trend: Consumer genomics is consolidating around the value of aggregated genetic databases rather than testing services, with each pharma-data deal raising both the price tag and the privacy stakes of who ultimately owns the cohort.